Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Comment by mstrmndon Jun 05, 2020 4:00pm
179 Views
Post# 31118200

RE:RE:RE:RE:RE:RE:RE:Echelon Doug Loe

RE:RE:RE:RE:RE:RE:RE:Echelon Doug LoeI'm going to take $340 M out of Dougie and Echelon - It's over Dougie!  We got you!  Where's your BS $1.40?  Lie huh?  These guys have made a killing killing companies - time to go to jail Dougie! 

GUD.KNIGHT ECHELON

qwerty22 wrote:

Do companies wait to the very last moment? The later you leave it the more you may be focused to accept the prevailing situation, external and internal factors. A conservative approach might say get it done earlier so it depends on the situation. 


I don't feel comfortable predicting these types of financing events other than knowing its inevitable. What would I do? Maybe small financing to get 12 months of cash. Get through the end of phase2 meeting with the fda and other milestones and get complete clarity on the Phase3 program then finance that with partnering/stock for the expensive Ph3. Idk.

 

MUGMODs wrote: Qwerty - agreed

On the financing side, how much time do you think we have ... business as usual ?
Let's assume we are not paying for P2/3 - someone else is taking this on.
Do we have enough cash to get us through the summer ?

If we do have enough ... the financing can pause.  So many good things could happen in the short term to drive the share price, making a financing a non-issue.

Just trying to get my mind around how much time we have before the cash is absolutely necessary.  It's a race against the clock now.

 

 



<< Previous
Bullboard Posts
Next >>